Royalty Payable

The Company entered into various agreements and subsequently received funding from investors for use by the Company for the research and development its OORT Product. In exchange for this funding, the Company agreed to provide investors with interest in the OORT Net Profit generated from its OORT Product in perpetuity. At December 31, 2018 and 2017, the Company determined an OORT Net Profit as a result of NARCAN® sales by Adapt. There was no OORT Net Profit prior to December 31, 2017. The following table sets forth the royalty payable to certain investors as of December 31, 2018 and December 31, 2017:



(in thousands)	Net Profit %		December 31, 2018		December 31, 2017

Potomac	10.2%	$	422	$	860
LYL	5.0%		206		421
Welmers	1.5%		62		127
Foundation	6.0%		248		—
Pendergast	1.0%		60		—
Royalty payable	23.7%	$	998	$	1,408